Clinical and genetic characteristics of patients with type 1 diabetes associated with interferon therapy

Diabetes Care

Volumn 34, Issue 2, 2011, Pages 471-473

  Nakanishi, Koji ^a,b   Saitoh, Satoshi ^b  

^a Okinaka Memorial Institute for Medical Research   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HLA A ANTIGEN; HLA DR ANTIGEN; INTERFERON;

ALLELE; ANTIBODY TITER; ARTICLE; CELL FUNCTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAPLOTYPE; HLA SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL;

ANTIVIRAL AGENTS; AUTOANTIBODIES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HEPATITIS C, CHRONIC; HLA ANTIGENS; HLA-A ANTIGENS; HLA-A24 ANTIGEN; HLA-DQ ALPHA-CHAINS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HLA-DRB1 CHAINS; HUMANS; INTERFERONS; MALE;

EID: 79951701801     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1237     Document Type: Article

References (15)

1. Booth JCL, O'Grady J, Neuberger J; The Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001;49(Suppl. 1):I1-I21
2. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-558 (Pubitemid 37186604)
3. Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-α treatment for chronic hepatitis C. Intern Med 2010;49:403-407
4. Scavone G, Zaccardi F, Manto A, Caputo S, Pitocco D, Ghirlanda G. A case of chronic hepatitis C developing insulin-dependent diabetes, thyroid autoimmunity and stiff-person syndrome as complications of interferon therapy. Diabetes Res Clin Pract 2010;89:e36-e38
5. Nakanishi K, Inoko H. Combination of HLA-A24, -DQA1*03, and -DR9 contributes to acute-onset and early complete β-cell destruction in type 1 diabetes: longitudinal study of residual β-cell function. Diabetes 2006;55:1862-1868
6. Nakanishi K, Watanabe C. Rate of β-cell destruction in type 1 diabetes influences the development of diabetic retinopathy: protective effect of residual β-cell function for more than 10 years. J Clin Endocrinol Metab 2008;93:4759-4766
7. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006;29:2462-2466 (Pubitemid 44912253)
8. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38:641-647 (Pubitemid 19125614)
9. Watanabe C, Nakanishi K. Type 1 diabetes induced by interferon therapy is characterized by high titer of GAD antibodies, raised level of serum interleukin 18, and relatively preserved β cell function (Abstract). Diabetes 2008;57(Suppl. 1):A355
10. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001;12:53-72 (Pubitemid 32294587)
11. Harrison LC, Honeyman MC, DeAizpurua HJ, et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993; 341:1365-1369 (Pubitemid 23159984)
12. Nakanishi K, Kobayashi T, Murase T, Naruse T, Nose Y, Inoko H. Human leukocyte antigen-A24 and -DQA1*0301 in Japanese insulin-dependent diabetes mellitus: independent contributions to susceptibility to the disease and additive contributions to acceleration of β-cell destruction. J Clin Endocrinol Metab 1999; 84:3721-3725 (Pubitemid 30645231)
13. Nejentsev S, Howson JMM, Walker NM, et al; Wellcome Trust Case Control Consortium. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007;450:887-892
14. Corghi DB, Gonçales NSL, Marques SBD, Gonçales FL Jr. Distribution of the human leukocyte antigen class II alleles in Brazilian patients with chronic hepatitis C virus infection. Braz J Med Biol Res 2008; 41:884-889
15. Yenigün A, Durupinar B. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 2002;76:1787-1789 (Pubitemid 34094626)